Nine therapies have outgrown the IPM growth
The Indian Pharma Market (IPM) clocked Rs 8014 crores in January 2016 and has grown at 9.1 per cent. Amongst the top 10, Mankind grew by 26.8 per cent, Lupin by 13.4 per cent and Macleods at 12.7 per cent.
Amongst the top 50 corporate, Bharat Serums had the highest growth of 34.8 per cent followed by Hetero at 29 per cent and Mankind at 26.8 per cent. 23 corporates have shown growths of more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporates, Alembic had the highest growth of 23 per cent followed by Aristo at 17.3 per cent and Glenmark at 16.3 per cent.
Amongst the 21-30 ranked corporates, FDC had the highest growth at 14.2 per cent followed by Cadila at 11.3 per cent and Novartis at 10 per cent. Amongst the 31-40 ranked corporates, Bharat Serums grew at 34.8 per cent followed by Hetero at 29 per cent and JBCPL at 13.5 per cent. Amongst the 41-50 ranked corporate, Troikaa has the highest growth at 21.5 per cent followed by Wallace* at 16.6 per cent and Systopic at 15.8 per cent.
Amongst the 51-60 ranked corporates, Boehringer Ingelheim grew at 49.5 per cent followed by Corona at 32.4 per cent and Centaur at 24.2 per cent. Amongst the 61-70 ranked corporates, RPG grew at 25.2 per cent followed by Geno which grew at 12 per cent and East India at 11.8 per cent. Amongst the 71-80 ranked corporates, Samarth grew at 21.3 per cent followed by Shreya at 20.2 per cent and Walter Bushnell at 18.2per cent. Amongst the 81-90 ranked corporates, Galpha grew at 49.2 per cent followed by Veritaz at 40.5 per cent followed by Dabur at 30.9 per cent. Amongst the 91-100 ranked corporate, Ozone grew at 30.2 per cent followed by Serum Institute at 25.9 per cent and Gland at 22.8 per cent.
The 100th biggest corporate was Gland Pharma and 150th biggest corporate was Claris in the IPM. MSD has entered the Rs 1000-crore club, Dey’s Medical, Ozone, Johnson & Johnson entered the Rs 100-crore club, Medo Pharma and La Renon entered the Rs 50-crore club on MAT Basis.
Indian companies have grown at 11.4 per cent versus 1.5 per cent for MNCs in January 2016. Amongst the top 50 in MNCs, Merck grew at 11.9 per cent followed by Novartis at 10 per cent and GSK at 6.1 per cent. Under the non-NLEM category Indian companies grew at 12.4 per cent whereas MNCs grew at 1.1 per cent.
The NLEM containing molecules market grew at 5.3 per cent whereas the non-DPCO market grew by 9.8 per cent and Non-Sch Para 19 Market at 6.4 per cent resulting in an overall growth of 9.1 per cent for January 2016. NLEM and Non – NLEM Category showed unit growth at 4.3 per cent and 2.5 per cent respectively.
Nine therapies have outgrown the IPM growth. Respiratory market grew at 17.8 per cent, gastrointestinal market grew at 11.7 per cent, pain and analgesics market grew at 8.1 per cent whereas anti -infectives grew at 11.9 per cent. The anti-diabetic market grew at 9.4 per cent and cardiac at 7.3 per cent in chronic business. Derma market grew by 9 per cent and urology market at 4.1 per cent. Anti-malarials de-grew at 20.1 per cent.
13 regions have outgrown the IPM growth. The Odisha market grew the highest at 20 per cent followed by Jharkhand at 19.4 per cent and Bihar at 19.3 per cent. The Tamil Nadu market grew at 1.7 per cent and two regions had negative growth in January 2016.
Amoxycillin + Clavulanic acid market grew at 16.4 per cent and Glimepiride + Metformin Market grew at 8.8 per cent. The markets of paracetamol grew at 28.4 per cent, Atorvastatin 1.3 per cent, Probiotic Microbes at 28.2 per cent, Cefixime 7.1 per cent, Pantoprazole 14.9 per cent, Montelukast + Levocetrizine at 15.3 per cent, Glimepiride + Metformin + Pioglitazone at 9.8 per cent, Vitamin-D at 19.4 per cent, Hydroquinone + Mometasone + Tretinoin at -9 per cent, Voglibose + Metformin + Glimepiride at 30.7 per cent, Rosuvastatin at 12.6 per cent, protein supplements at 11.4 per cent, Azithromycin at 17.1 per cent, calcium carbonate + Vit D3 market at 0.8 per cent, Paracetamol + Phenylephrine + Chlorpheniramine at 15.2 per cent, Meropenem at 45.1 per cent, Montelukast + Fexofenadine at 36.9 per cent. The 50th biggest market is Sildenafil and 100th biggest market is Cefalexin.
Mixtard leads the pack with Rs 31 crores followed by Corex at Rs 29 crores, Glycomet GP & Augmentin at Rs 28 crores for January 2016. Few Brands who have gained ranks include Aciloc RD (+94), Electral Powder (+68), Unwanted Kit (+64), Rotarix (+47), Meronem (+43), Duolin (+39), Betnesol (+30), Rabipur (+28), Vertin (+27), Jalra M (+26), Ultracet, Betnovate N (+23), Deriphyllin (+21), Sapsmoproxyvon Plus (+20), Monocef –O (+18), Trajenta (+17)< Budecort (+16), Betnovate C , Dolo (+15), Levipil (+14), Voveran, Pamderm Plus, Telma, Rosuvas, Ascoril Plus (+13), Pan, Calpol, Thyronorm, Januvia, Azithral (+12), Janumet (+11), Telma H, Pantocid D SR (+10), Taxim-O, Moxikind CV, Gluconorm-G (+9), GalvusMet, Susten, Rantac, Pantop (+8), Clavam, Sinarest (+4) amongst top 100 brands over January 2015.
Mero (+182), Finecef (+151), Lobate GM (+107), Zerodol SP, Pipzo (+88), Enterogermina (+87), Cilacar (+76), P (+75), Brilinta, Moxclav (+68), Grilinctus (+41), Bevon (+25) are few brands in 101-200 ranked brands. Few brands that have moved up ranks fastest into Top 300 Brands are Ocid, Grafeel, Similac, Candiforce, Reditux, Anafortan, Mero. The 300th biggest brand is Reditux from DRL.
A total of 239 brands and 401 SKUs were launched in January 2016. The top new brands are Ledviclear, Sofab LP, Hepcinat LP. Three brands were launched in Sofosbuvir + Ledipasavir category. Within the VMS category are Folyblend (Akesiss), Pforu (Galpha), Macgesia (Macleods), within anti-diabetic are Kmet Duo (Blue Cross), Glurest M (Alde Medi Impex), Satrvog GM ( Merck) and within respiratory, we see Solitair (Blue Cross), Monokast FX, Monokast (TTK), Ebmont FX3 (MMC). The biggest new launch by a MNC is Ledviclear in January 2016.
PharmaTrac is a the secondary sales data audit conducted
by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocdawacs.com/